uniQure (NASDAQ:QURE) Stock Price Down 3.5% – Time to Sell?

Shares of uniQure (NASDAQ:QURE) dropped 3.5% during trading on Monday . The stock traded as low as $17.21 and last traded at $17.32. Approximately 85,917 shares changed hands during trading, a decline of 86% from the average daily volume of 603,523 shares. The stock had previously closed at $17.94.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on QURE. Leerink Partners upped their price objective on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Mizuho upped their price objective on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Price Performance

The company has a market cap of $775.99 million, a price-to-earnings ratio of -3.21 and a beta of 0.41. The stock has a 50 day simple moving average of $10.83 and a two-hundred day simple moving average of $7.85. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, equities research analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the business. RTW Investments LP acquired a new stake in uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc purchased a new stake in uniQure during the 3rd quarter worth about $53,000. Quarry LP acquired a new stake in uniQure in the 3rd quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.